MGMugdha Gokhale

Mugdha Gokhale

*This is an algorithmically generated author record based on publicly available information.

Mugdha Gokhale has a total of 47 co-authors. Here are the top co-authors by number of shared publications:

  • Til Stürmer

    Department of Epidemiology, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC

    6 shared publications
  • Virginia Pate

    Department of Epidemiology, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC

    6 shared publications
  • John B. Buse

    University of North Carolina School of Medicine, Chapel Hill, USA

    4 shared publications
  • John B. Buse

    Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina

    3 shared publications
  • Michele Jonsson Funk

    Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapell Hill, NC, USA

    3 shared publications
  • Jennifer Lund

    Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapell Hill, NC, USA

    2 shared publications

Latest Publications

  • Healthcare resource utilization, costs, and survival among Medicare beneficiaries with relapsed or refractory DLBCL receiving second-line therapy: a real-world evidence study

    by Mugdha Gokhale, Philip K. Chan, Wei Jiang, Rebecca Levin, Joseph C. Cappelleri, Virginia Noxon-Wood, Anthony Yu, Ilya Okunev

    Chemotherapy is the main treatment for diffuse large B-cell lymphoma (DLBCL); yet 30-40% of patients are considered relapsed or refractory (R/R) to initial therapy and have second-line therapy (2 L). There is a need to study real-world outcomes to address the changing treatment landscape for R/R DLBCL patients. This study examined treatment patterns, healthcare utilization and costs, and survival among Medicare R/R DLBCL patients from 2016 to 2022. Study patients (n = 3,191) were an average of 75.7 years old and only 30.6% of patients initiated 3 L. Patients with 3 L incurred higher costs ($15,133 per-patient per-month [PPPM]) than all patients ($9,487 PPPM). Half of patients died within 6.7 months from start of 2 L. Patients with older age and elevated comorbidity burden had significantly shorter survival times within 3 years after 2 L initiation. Our analyses indicate a high disease burden among R/R DLBCL patients, highlighting the need for new treatments.


  • Decreased Antihyperglycemic Drug Use Driven by High Out-of-Pocket Costs Despite Medicare Coverage Gap Closure

    by Mugdha Gokhale, Stacie B. Dusetzina, Virginia Pate, Danielle S. Chun, John B. Buse, Til Stürmer, Emily W. Gower

    OBJECTIVE: Using the 2016 Medicare Part D coverage gap as an example, we explored effects of increased out-of-pocket costs on adherence to branded dipeptidyl peptidase 4 inhibitors (DPP-4i) in patients without financial subsidies relative to subsidized patients who do not experience increased spending during the gap. We also explored seasonality of reinitiation, because discontinuers may be more likely to reinitiate in January when benefits reset. RESEARCH DESIGN AND METHODS: We identified DPP-4i or sulfonylurea initiators, aged ≥66 years, from a 20% sample of 2015–2016 Medicare claims. Difference-in-differences Poisson regression was used to compare adherence before and after entering the coverage gap between nonsubsidized and subsidized patients. Among discontinuers, monthly hazard ratios (HRs) for reinitiation relative to January 2016 were derived with Cox models. As a second control, we repeated analyses using sulfonylureas, generic low-cost alternatives. RESULTS: In 2016, 8,096 subsidized and 6,173 nonsubsidized DPP-4i initiators entered the coverage gap. For nonsubsidized patients, copayment in the coverage gap was 45% ($227 per DPP-4i prescription), and adherence decreased from 68.4% to 49.0% after gap entry. Accounting for adherence differences in subsidized patients, nonsubsidized patients demonstrated reduced adherence to DPP-4i (difference-in-difference: −16.9%; 95% CI −18.7%, −15.1%) but not sulfonylureas (−1.6%; 95% CI −3.4%, 0.2%). Reinitiation was lowest in the months before January (HR 0.4–0.5) among nonsubsidized DPP-4i patients, demonstrating a strong seasonal pattern. CONCLUSIONS: Increased out-of-pocket costs negatively affect adherence and reinitiation of branded antihyperglycemic drugs among patients without financial subsidies. Despite closure of the coverage gap, affordability remains a concern given increasing list prices for many drugs on Medicare and the growing use of deductibles and coinsurance by commercial health plans.


  • Linking electronic health data in pharmacoepidemiology: Appropriateness and feasibility

    by Donna R. Rivera, Mugdha N. Gokhale, Matthew W. Reynolds, Elizabeth B. Andrews, Danielle Chun, Kevin Haynes, Michele L. Jonsson‐Funk, Kristine E. Lynch, Jennifer L. Lund, Helen Strongman, et al.

    Purpose: To provide guidance on data linkage appropriateness and feasibility to plan purposeful and sustainable new linkages that advance pharmacoepidemiology and healthcare research. Planning a new data linkage requires careful evaluation to weigh the resources required with the potential overall benefits.Methods: In response to an International Society for Pharmacoepidemiology (ISPE) call for manuscripts, a working group comprised of members from academic, industry, and government determined priority content areas; appropriateness and feasibility of data linkage was selected. Within this topic, scientific and operational considerations were determined, reviewed, and formulated into key areas, and translated into 12 consensus recommendations.Results: Guidance for feasibility assessment was categorized into five key areas: (1) research objectives and justification; (2) data quality and completeness; (3) the linkage process; (4) data ownership and governance; and (5) overall value added by linkage. Within these key areas, recommendations to consider prior to initiation were developed to evaluate suitability of the linkage to meet research objectives, assess source data completeness and population coverage, and ensure well‐defined data governance standards and protections. When creating novel linked datasets, researchers must assess the feasibility of both scientific (data quality and linkage methods) and operational (access, data use and transfer, governance, and cost) aspects.Conclusions: The data linkage feasibility assessment considerations outlined can be used as a guide when designing sustainable linked data resources to generate actionable evidence in healthcare research. These recommendations were constructed for wide applicability and can be adapted depending on the geographic, structural, and data components of the linkage.


  • Open Access

    Prevalence of Eosinophilic Granulomatosis With Polyangiitis and Associated Health Care Utilization Among Patients With Concomitant Asthma in US Commercial Claims Database

    by Mugdha Gokhale, Christopher F. Bell, Scott Doyle, Jolyon Fairburn-Beech, Jonathan Steinfeld, Melissa K. Van Dyke

    Objective: To estimate the prevalence and associated disease burden of eosinophilic granulomatosis with polyangiitis (EGPA) in patients with asthma from a US claims database. Methods: Two cohorts were defined using enrollees (aged ≥18 years) from the Optum deidentified Clinformatics Datamart claims database 2010–2014, based on validated EGPA case definitions with varying specificity: EGPA 1 (main cohort; more specific; patients with 2 codes [in any combination] within 12 months of each other for eosinophilia, vasculitis, or mononeuritis multiplex) and EGPA 2 (sensitivity analysis cohort; less specific; patients with 2 codes of above conditions and/or neurologic symptoms within 12 months of each other). Patients had 3 or more asthma medications in the 12-month baseline before index date (date of the second code). Eosinophilic granulomatosis with polyangiitis prevalence, asthma severity during the baseline period, oral corticosteroid (OCS) use, and health care utilization during the 12-month follow-up period were determined. Results: Overall, 88 and 604 patients were included in main cohort EGPA 1 and sensitivity analysis cohort EGPA 2, respectively; corresponding annual EGPA prevalence rates were 3.2 to 5.9 and 23.4 to 30.7 cases/million patients. Approximately 75% of patients were prescribed OCS and ~30% experienced 1 or more hospitalization; 75% in EGPA 1 and 52% in EGPA 2 with 1 or more non-OCS prescription in the 90 days before index date had severe asthma. Conclusions: Eosinophilic granulomatosis with polyangiitis prevalence estimates varied based on specificity of the case definition but were generally consistent with previous country-specific estimates. Despite differences in prevalence, both cohorts displayed a generally similar, high burden of OCS use and health care utilization, highlighting the substantial disease burden among patients with EGPA and the need for specific treatments.


  • Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type‐2 diabetes

    by Elizabeth M. Garry, John B. Buse, Mugdha Gokhale, Jennifer L. Lund, Matthew E. Nielsen, Virginia Pate, Til Stürmer

    Aim: The aim of the study was to empirically demonstrate the effect of varying study designs when evaluating the safety of pioglitazone in treating bladder cancer. Methods: We identified Medicare beneficiaries above 65 years of age with diabetes between 2008 and 2015 and with classified exposure (at least two claims within 180 days) to glucose‐lowering drugs (GLD), pioglitazone or another drug. The effects of varying the following study design parameters on bladder cancer risk were assessed: use of a new vs existing drug, choice of referent (all non‐users and users of GLDs, non‐insulin GLDs and DPP‐4s) and whether or not censoring accounted for treatment change. We used the Cox proportional hazards model to obtain adjusted HRs and 95% CIs. Results: We included 1,510,212 patients classified as pioglitazone users (N = 135,188) or non‐users (N = 1,375,024). Users had more diabetic complications than non‐users, but fewer than insulin users. The HR ranged from 1.10 (1.01‐1.20) to 1.13 (0.99‐1.29) when censoring ignored treatment change, suggesting a weak association or none between pioglitazone and bladder cancer, probably under‐estimating risk. However, the HR was 1.20 (1.01‐1.42) when cohorts were restricted to new users, censored upon treatment change, and when DPP‐4 was used as the referent, suggesting an increased risk of bladder cancer associated with pioglitazone. Conclusions: The continued demand for new GLDs indicates the need for more robust observational methods to improve the value of generating real‐world evidence in equipping clinicians to make informed prescribing decisions. Although there is no one‐size‐fits‐all approach, we recommend active comparator new user study designs that compare therapeutically equivalent drugs and account for treatment changes during follow‐up to present the least biased comparative safety estimates.


  • Impact of metformin use on the cardiovascular effects of dipeptidyl peptidase‐4 inhibitors: An analysis of Medicare claims data from 2007 to 2015

    by Matthew J. Crowley, Mugdha Gokhale, Virginia Pate, Til Stürmer, John B. Buse

    Aims: To examine the outcomes of dipeptidyl peptidase‐4 (DPP‐4) inhibitor initiation with and without concurrent metformin treatment. Materials and methods: We identified Medicare enrollees initiating a DPP‐4 inhibitor, a sulphonylurea or a thiazolidinedione. Using propensity‐score‐weighted Poisson models, we evaluated 1‐year cardiovascular (CV) outcome incidence among initiators of DPP‐4 inhibitors versus comparators in subgroups with and without concurrent metformin use, and assessed the interaction between initiation drug and metformin. Outcomes included mortality, non‐fatal myocardial infarction (MI), stroke, and a composite outcome. Results: For the DPP‐4 inhibitor (n = 13 391) versus sulphonylurea (n = 33 206) comparison, rate differences in composite outcome incidence favoured DPP‐4 inhibitors: −2.0/100 person‐years among metformin users (95% confidence interval [CI] −2.7 to −1.3) and − 1.0/100 person‐years (95% CI −1.8 to −0.2) among metformin non‐users. Similar rate difference trends among metformin users and non‐users were seen for mortality (−1.5/100 person‐years [95% CI −2.1 to −0.9] and −0.7/100 person‐years [95% CI −1.4 to 0.0]) and non‐fatal MI (−0.5/100 person‐years [95% CI −0.8, −0.3] and 0.1/100 person‐years [95% CI −0.2 to 0.4]). The interaction between DPP‐4 inhibitor initiation and metformin was statistically significant for non‐fatal MI ( P = 0.008). For the DPP‐4 inhibitor (n = 22 210) versus thiazolidinedione (n = 9517) comparison, rate differences in composite outcome incidence for DPP‐4 inhibitor initiation were −0.6/100 person‐years (95% CI −1.5 to 0.2) among metformin users and 1.0 (95% CI 0.0 to 2.0) among metformin non‐users. Similar rate difference trends among metformin users and non‐users were seen for mortality (−0.5/100 person‐years [95% CI −1.3 to 0.1] and 0.8/100 person‐years [95% CI −0.0 to 1.7]) and non‐fatal MI (−0.1/100 person‐years [95% CI −0.4 to 0.2] and 0.2/100 person‐years [95% CI −0.1 to 0.6]). The interaction between DPP‐4 inhibitor initiation and metformin was statistically significant for the composite outcome ( P = 0.024) and mortality ( P = 0.023). Conclusion: Incidence rate differences in multiple CV outcomes appeared more favourable when DPP‐4 inhibitor initiation occurred in the presence of metformin, suggesting a possible interaction between DPP‐4 inhibitors and metformin.


  • Calendar time as an instrumental variable in assessing the risk of heart failure with antihyperglycemic drugs

    by Mugdha Gokhale, John B. Buse, Christina DeFilippo Mack, Michele Jonsson Funk, Jennifer Lund, Ross J. Simpson, Til Stürmer

    Objective: In recent years, second‐line diabetes treatment with dipeptidyl peptidase–4 inhibitors (DPP‐4i) increased with a corresponding decrease in thiazolidinediones (TZDs). Using hospitalization for heart failure (HF) as a positive control outcome, we explored the use of calendar time as an instrumental variable (IV) and compared this approach to an active comparator new‐user study.Methods: We identified DPP‐4i or TZD initiators after a 6‐month washout using Medicare claims 2006–2013. The IV was defined as a binary variable comparing initiators during October 2010 to December 2013 (postperiod) versus January 2008 to May 2010 (preperiod). We examined IV strength and estimated risk differences (RDs) for HF using Kaplan‐Meier curves, which were compared with propensity score (PS)–weighted RD for DPP‐4i versus TZD.Results: The IV compared 22 696 initiators (78% DPP‐4i) in the postperiod versus 20 283 initiators (38% DPP‐4i) in the preperiod, resulting in 40% compliance. The active‐comparator (PS‐weighted) approach compared 26 198 DPP‐4i and 18 842 TZD initiators. Covariate balance across IV levels was slightly better than across treatments (standardized difference, 3% vs 4.5%). The 1‐ and 2‐year local average treatment effects of RD of HF per 100 patients in the “compliers” (95% confidence intervals) were −0.62 (−0.99 to −0.25) and −0.88 (−1.46 to −0.25). Corresponding PS‐weighted results were −0.20 (−0.33 to −0.05) and −0.18 (−0.30 to 0.03).Conclusion: Both approaches indicated lesser risk of HF hospitalizations among DPP‐4i vs TZD initiators. The magnitude of the estimated effects may differ due to differences in the target populations and assumptions. Calendar time can be leveraged as an IV when market dynamics lead to profound changes in treatments.


  • Open Access

    No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase‐4 inhibitors vs therapeutic alternatives

    by Mugdha Gokhale, John B. Buse, Michele Jonsson Funk, Jennifer Lund, Virginia Pate, Ross J. Simpson, Til Stürmer

    Aim: To compare the cardiovascular ( CV ) risk associated with dipeptidyl peptidase‐4 ( DPP ‐4) inhibitors relative to sulphonylureas ( SUs ) and thiazolidinediones ( TZDs ). Methods: During 2007 to 2013, using M edicare data for beneficiaries aged >65 years, we identified the following 2 cohorts of new‐users, who had not been exposed to the drugs being compared in the 6 months before initiation: (1) DPP ‐4 inhibitor vs SU initiators and (2) DPP ‐4 inhibitor vs TZD initiators. Using propensity‐score‐adjusted C ox models accounting for competing risk by death, we estimated the hazard ratios ( HRs ), risk differences and 95% confidence intervals ( CIs ) for myocardial infarction ( MI ), stroke, hospitalization for heart failure ( HF ), and a combined outcome ( MI , stroke, all‐cause mortality). Results: In the DPP ‐4 inhibitor vs SU comparison, there were 30 130 DPP ‐4 inhibitor initiators and 68 382 SU initiators. Their mean age was 75 years, 41% were men and 55% had a baseline CV condition. The HR for the composite outcome was 0.75 (95% CI 0.72‐0.79) over a median treatment duration of 1 year, but the 1‐year risks of MI were 1.00 (95% CI 0.89‐1.12) and 1.47 (95% CI 1.38‐1.56) per 100 patients for DPP ‐4 inhibitors and SUs , respectively, and the corresponding stroke risks were 0.98 (95% CI 0.87‐1.10) and 1.09 (95% CI 1.01‐1.17). For the DPP ‐4 inhibitor vs TZD comparison, there were 20 596 DPP ‐4 inhibitor initiators and 13 526 TZD initiators without previous HF . Their mean age was 74 years, 42% were men and 30% had a baseline CV event. The composite outcome HR was 0.94 (95% CI 0.86‐1.02) over a median treatment duration of 1 year. The 1‐year risk for MI was ~0.90 and for stroke it was ~0.80 per 100 patients in both DPP ‐4 inhibitor and TZD initiators. Conclusion: Although limited by the short treatment period, the present study suggests there is no increased short‐term risk of MI , stroke or HF with DPP ‐4 inhibitors vs SUs / TZDs .


  • Comparison of diagnostic evaluations for cough among initiators of angiotensin converting enzyme inhibitors and angiotensin receptor blockers

    by Mugdha Gokhale, Cynthia Girman, Yong Chen, Virginia Pate, Michele Jonsson Funk, Til Stürmer

    Purpose Differential diagnostic evaluation associated with a drug may bias effect estimates because of an increased detection of preclinical outcomes. Persistent cough is a common side effect with angiotensin‐converting enzyme inhibitors (ACEI), and we hypothesized that ACEI initiators would undergo more diagnostic evaluations, potentially leading to diagnosis of preclinical lung cancer. We compared the incidence of cough‐related diagnostic evaluations and lung cancer among ACEI versus angiotensin receptor blockers (ARB) initiators. Methods Using a 20% sample of Medicare claims 2007–2012, we identified initiators of ACEI or ARB, age 66–99 years. Incidence of diagnostic evaluation and lung cancer were compared using adjusted Cox models. Monthly probabilities of workup were compared using proportion differences. Results There were 342 611 and 108 116 ACEI and ARB initiators, respectively. Monthly probability of chest X‐rays ranged from minimum 4.7% to maximum 21.2% in the 6 months pre and post‐initiation. Differences in incidence of diagnostic procedures in the 6 months after initiation were only minimal (chest X‐rays hazard ratio (HR) = 1.12; 95% CI: 1.10–1.14), chest‐MRI (0.86, 95% CI: 0.74–0.99), CT‐scans (1.09, 95% CI: 0.99–1.18) or bronchoscopies (1.03, 95% CI: 0.83–1.29). Proportion differences for chest X‐rays peaked in the month pre‐initiation (8.4%, 95% CI: 8.1–8.6) but negligible thereafter. There was no difference in the incidence of lung cancer among ACEI versus ARB initiators (HR = 0.99, 95% CI: 0.84–1.16). Conclusion Results indicate minimal differential chest workup after ACEI versus ARB initiation and no difference in lung cancer incidence, but suggest differential workup in the month before the first recorded prescription. The latter may reflect drug use before the first observed pharmacy claim or increased workup before initiation of ACEI therapy. Copyright © 2016 John Wiley & Sons, Ltd.